Stimulant Use Disorder

Clinical picture

• Binge use over hours to days is followed by a crash of hypersomnia, hyperphagia, dysphoria, and intense craving that closely mimics major depression.
• Acute intoxication brings euphoria, hypervigilance, pressured speech, mydriasis, bruxism, tachycardia, hypertension, and hyperthermia.
• Prolonged methamphetamine use produces paranoia, tactile hallucinations, stereotyped behaviors, dental decay, and excoriated skin lesions.
• Cognitive complaints of poor memory, sustained attention, and decision-making persist for weeks to months after the last use.
• Sexualized use, especially in chemsex contexts, raises HIV and sexually transmitted infection risk and complicates honest disclosure.
• Cardiovascular emergencies include chest pain, arrhythmia, aortic dissection, myocardial infarction, and hemorrhagic stroke in young patients.

Criteria snapshot

• Diagnosed when at least 2 of 11 criteria occur within 12 months, with the class specified as amphetamine-type, cocaine, or other stimulant.
• Severity is mild 2-3, moderate 4-5, or severe 6 or more, and a prescribed-medication exclusion applies to tolerance and withdrawal.
• Stimulant withdrawal is a separate diagnosis requiring dysphoric mood plus at least 2 physiologic changes within hours to days of stopping.
• Stimulant-induced psychotic disorder applies when psychosis exceeds what intoxication explains and warrants independent clinical attention.
• Remission specifiers require no criteria other than craving for 3 to under 12 months (early) or for 12 months or more (sustained).

Neurobiology

• Cocaine blocks dopamine, norepinephrine, and serotonin reuptake, while amphetamines additionally reverse DAT and empty vesicular stores.
• The resulting nucleus accumbens dopamine surge is far larger and faster than that from natural rewards, driving powerful incentive salience.
• Chronic use downregulates striatal D2 receptors, blunting response to ordinary reinforcers and producing durable anhedonia and amotivation.
• Methamphetamine is neurotoxic to dopaminergic and serotonergic terminals, with only partial recovery over 12 to 24 months of abstinence.
• Glutamatergic remodeling of prefrontal-to-accumbens projections underlies cue-induced craving and its incubation across early abstinence.
• Sympathomimetic load causes vasoconstriction, accelerated atherosclerosis, cardiomyopathy, and hyperthermia with rhabdomyolysis.

Psychology

• Incentive sensitization makes drug cues progressively more attention-grabbing even as the subjective pleasure of use steadily declines.
• Craving incubates rather than fades, peaking weeks to months into abstinence and catching patients off guard after early success.
• Use is often functional at first, sustaining long work shifts, controlling weight, or countering depressive and ADHD symptoms.
• Conditioned cues include paraphernalia, cash, music, and sexual contexts, all of which require explicit stimulus-control planning.
• Post-binge shame and cognitive impairment undercut follow-through, so early sessions should be brief, concrete, and tightly structured.

Differential & comorbidity

• Distinguish stimulant-induced psychosis, which usually clears within days to a month of abstinence, from a primary schizophrenia spectrum disorder.
• Screen for untreated ADHD and bipolar disorder, both common in this population and both substantially changing the treatment plan.
• Co-use of opioids and fentanyl-adulterated stimulants now drives many overdose deaths, so provide overdose education to every patient.
• Expect high rates of depression, PTSD, HIV, hepatitis C, and methamphetamine-associated pulmonary hypertension and cardiomyopathy.
• Agitation with hyperthermia is a medical emergency: give benzodiazepines first, cool actively, and avoid relying on physical restraint.

Pharmacologic treatment

• No medication is FDA-approved for stimulant use disorder, so treatment is behavioral first with pharmacotherapy as an adjunct in selected patients.
• Combined bupropion 300-450 mg/day with naltrexone 380 mg IM showed modest benefit for methamphetamine use disorder in the ADAPT-2 trial.
• Topiramate for cocaine and mirtazapine 30 mg/night for methamphetamine have limited but positive randomized trial support.
• Prescription psychostimulant agonist therapy remains investigational and should be avoided outside research or specialist addiction settings.
• Treat comorbidity directly with long-acting stimulants or bupropion for ADHD, and brief antipsychotic use for persistent stimulant psychosis.

Psychotherapy

• Contingency management is the single most effective intervention when incentives are of sufficient magnitude, frequency, and immediacy.
• The community reinforcement approach plus vouchers outperforms standard drug counseling across multiple randomized controlled trials.
• CBT with relapse prevention over 12 to 16 sessions addresses cue exposure, refusal skills, and structured lapse management.
• The Matrix Model, a 16-week structured intensive outpatient program, remains the benchmark for methamphetamine use disorder.
• Motivational interviewing engages ambivalent patients, particularly when use serves functional goals such as work performance.

Adjunct options

• Expect cognitive impairment early, so use written plans, repetition, appointment reminders, and shorter sessions during the first month.
• Address sleep, nutrition, and dental care, and normalize that anhedonia improves over 4 to 12 weeks rather than medicating it reflexively.
• Provide naloxone, fentanyl test strips, and HIV pre-exposure prophylaxis, particularly for patients in sexualized use contexts.
• Use ASAM criteria for level of care, with intensive outpatient or residential placement for patients facing unstable housing.
• Track outcomes with urine drug testing tied to incentives, plus validated craving, psychiatric, and functional status measures.

Clinical pearls

• Contingency management outperforms every medication studied for stimulant use disorder.
• Psychosis persisting a month past abstinence points to a primary psychotic disorder.
• Craving incubates: warn patients that week 6 can feel worse than week 1 did.